1.
|
Eriksson B and Oberg K: Neuroendocrine
tumours of the pancreas. Br J Surg. 87:129–131. 2000. View Article : Google Scholar
|
2.
|
Takahashi Y, Akishima-Fukasawa Y,
Kobayashi N, et al: Prognostic value of tumor architecture,
tumor-associated vascular characteristics, and expression of
angiogenic molecules in pancreatic endocrine tumors. Clin Cancer
Res. 13:187–196. 2007. View Article : Google Scholar
|
3.
|
Miljković MD, Girotra M, Abraham RR and
Erlich RB: Novel medical therapies of recurrent and metastatic
gastroenteropancreatic neuroendocrine tumors. Dig Dis Sci. 57:9–18.
2011.PubMed/NCBI
|
4.
|
Jain RK, Duda DG, Clark JW and Loeffler
JS: Lessons from phase III clinical trials on anti-VEGF therapy for
cancer. Nat Clin Pract Oncol. 3:24–40. 2006. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Kasuya K, Nagakawa Y, Suzuki M, Tanaka H,
Ohta H, Itoi T and Tsuchida A: Anti-vascular endothelial growth
factor antibody single therapy for pancreatic neuroendocrine
carcinoma exhibits a marked tumor growth-inhibitory effect. Exp
Ther Med. 2:1047–1052. 2011.
|
6.
|
Grindey GB, Hertel LW and Plunkett W:
Cytotoxicity and antitumor activity of 2′,2′-difluorodeoxycytidine
(gemcitabine). Cancer Invest. 8:313–318. 1990.
|
7.
|
Shirasaka T, Shimamato Y, Ohshimo H,
Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a
novel form of an oral 5-fluorouracil derivative (S-1) directed to
the potentiation of the tumor selective cytotoxicity of
5-fluorouracil by two biochemical modulators. Anticancer Drugs.
7:548–557. 1996. View Article : Google Scholar
|
8.
|
Georgieva I, Koychev D, Wang Y, Holstein
J, Hopfenmüller W, Zeitz M and Grabowski P: ZM447439, a novel
promising aurora kinase inhibitor, provokes antiproliferative and
proapoptotic effects alone and in combination with bio- and
chemotherapeutic agents in gastroenteropancreatic neuroendocrine
tumor cell lines. Neuroendocrinology. 91:121–130. 2010. View Article : Google Scholar
|
9.
|
Shah DK, Veith J, Bernacki RJ and
Balthasar JP: Evaluation of combined bevacizumab and
intraperitoneal carboplatin or paclitaxel therapy in a mouse model
of ovarian cancer. Cancer Chemother Pharmacol. 68:951–958. 2011.
View Article : Google Scholar : PubMed/NCBI
|
10.
|
Braakhuis BJ, Ruiz van Haperen VW, Boven
E, Veerman G and Peters GJ: Schedule-dependent antitumor effect of
gemcitabine in in vivo model system. Semin Oncol. 4(Suppl 11):
42–46. 1995.PubMed/NCBI
|
11.
|
Fukushima M, Satake H, Uchida J, et al:
Preclinical antitumor efficacy of S-1: a new oral formulation of
5-fluorouracil on human tumor xenografts. Int J Oncol. 13:693–698.
1998.PubMed/NCBI
|
12.
|
Nakahira S, Nakamori S, Tsujie M, et al:
Pretreatment with S-1, an oral derivative of 5-fluorouracil,
enhances gemcitabine effects in pancreatic cancer xenografts.
Anticancer Res. 28:179–186. 2008.PubMed/NCBI
|
13.
|
Yao JC, Phan A, Hoff PM, et al: Targeting
vascular endothelial growth factor in advanced carcinoid tumor: a
random assignment phase ll study of depot octreotide with
bevacizumab and pegylated interferon alpha-2b. Clin Oncol.
26:1316–1323. 2008. View Article : Google Scholar
|
14.
|
Pour PM and Kazakoff K: Stimulation of
islet cell proliferation enhances pancreatic ductal carcinogenesis
in the hamster model. Am J Pathol. 149:1017–1025. 1996.PubMed/NCBI
|
15.
|
Kindler HL, Niedzwiecki D, Hollis D, et
al: Gemcitabine plus bevacizumab compared with gemcitabine plus
placebo in patients with advanced pancreatic cancer: phase III
trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin
Oncol. 28:3617–3622. 2010. View Article : Google Scholar : PubMed/NCBI
|
16.
|
Masellis AM, Sielaff TD and Bender GP:
Successful treatment of metastatic pancreatic adenocarcinoma with
combination chemotherapy regimens. Int J Clin Oncol. 14:478–481.
2009. View Article : Google Scholar : PubMed/NCBI
|
17.
|
Nakai Y, Isayama H, Sasaki T, et al:
Impact of S-1 on the survival of patients with advanced pancreatic
cancer. Pancreas. 39:989–993. 2010. View Article : Google Scholar : PubMed/NCBI
|
18.
|
Murakami Y, Uemura K, Sudo T, Hayashidani
Y, Hashimoto Y, Ohge H and Sueda T: Impact of adjuvant gemcitabine
plus S-1 chemotherapy after surgical resection for adenocarcinoma
of the body or tail of the pancreas. J Gastrointest Surg. 13:85–92.
2009. View Article : Google Scholar : PubMed/NCBI
|
19.
|
Yamada Y, Yamaguchi T, Matsumoto H, et al:
Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB)
as first-line therapy for patients with metastatic colorectal
cancer. Invest New Drugs. Sept 6–2011.(E-pub ahead of print).
|
20.
|
Oberg K, Akerström G, Rindi G and Jelic S;
ESMO Guidelines Working Group: Neuroendocrine
gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines
for diagnosis, treatment and follow-up. Ann Oncol. 21(Suppl 5):
v223–v227. 2010. View Article : Google Scholar
|
21.
|
Villaume K, Blanc M, Gouysse G, et al:
VEGF secretion by neuroendocrine tumor cells is inhibited by
octreotide and by inhibitors of the PI3K/AKT/mTOR pathway.
Neuroendocrinology. 91:268–278. 2010. View Article : Google Scholar : PubMed/NCBI
|